Ainos Inc. (AIMDW)
undefined
undefined%
At close: undefined
0.14
0.00%
After-hours Jan 06, 2025, 03:57 PM EST

Company Description

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications.

The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.

It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products.

Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021.

The company was incorporated in 1984 and is based in San Diego, California.

Ainos Inc.
Ainos Inc. logo
Country United States
IPO Date n/a
Industry Biotechnology
Sector Healthcare
Employees 46
CEO Chun-Hsien Tsai

Contact Details

Address:
8880 Rio San Diego Drive
San Diego,
United States
Website https://www.ainos.com

Stock Details

Ticker Symbol AIMDW
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001014763
CUSIP Number 00902F113
ISIN Number US00902F1131
Employer ID 75-1974352
SIC Code 2834

Key Executives

Name Position
Chun-Hsien Tsai Chairman of Board, President & Chief Executive Officer
Hsin-Liang Lee Chief Financial Officer
Chih-Heng Lu Director of Corporate Developoment

Latest SEC Filings

Date Type Title
Dec 30, 2024 S-3/A [Amend] Filing
Dec 23, 2024 S-3 Filing
Dec 04, 2024 8-K Current Report
Nov 27, 2024 4 Filing
Nov 27, 2024 4 Filing
Nov 27, 2024 4 Filing
Nov 27, 2024 4 Filing
Nov 27, 2024 SC 13D/A [Amend] Filing
Nov 15, 2024 4 Filing
Nov 15, 2024 4 Filing